Genialis krasID, the first AI/ML biomarker algorithm that can predict patient response and clinical benefit to KRAS ...

Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

(Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of ...

These compounds were used to represent: Targeted drugs which block a cancer-causing protein called KRAS G12C. These have been approved for use in lung cancer, but often fail to benefit patients in the ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Q2 2024 Earnings Call Transcript September 24, 2024 Operator: Good morning, and welcome to the Altamira Therapeutics First ...

The inhibition of ERK5 is a potential complementary strategy for countering FAK inhibitor resistance in patients with lung ...

To see if cryptic pockets were also present on other GTPases, Shokat and coworkers overlaid the sequence of these enzymes ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to ...